Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients with Psoriasis who had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT
Main Article Content
Keywords
Bimekizumab, Psoriasis, Efficacy, Safety, Quality of life, Clinical trial, Long-term, BE RADIANT
Abstract
References
1. Yeung H et al. J Am Acad Dermatol 2013;68:64–72
2. Schmitt-Egenolf M et al. Dermatol Ther (Heidelb) 2021;11:2107–21
3. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884
4. Hongbo Y et al. J Invest Dermatol 2005;125:659–64
2. Schmitt-Egenolf M et al. Dermatol Ther (Heidelb) 2021;11:2107–21
3. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884
4. Hongbo Y et al. J Invest Dermatol 2005;125:659–64